PEPTIDE CORTEXThe library
← The library

Ipamorelin

researchGH Axis
Evidence grade
DResearch/compounded/adjunct (no established FDA indication)
Cardiovascular · 0–5 · separate axis
1
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeGH axis
MechanismGhrelin receptor agonist (GHS): stimulates GH release
EffectsSignals the GH axis; can affect body composition, fluid retention, and glucose
DosingNo human dose established.
Bottom linePopular in research/compounding; human safety/benefit not well-established.
Protocols · as published2 sourced
Clinical trialPhase 2, postoperative ileus (Beck, Int J Colorectal Dis 2014)
RouteIntravenous infusion
FrequencyTwice daily, postoperative day 1-7 or discharge
Starting0.03 mg/kg IV
EscalationNone
Target0.03 mg/kg IV twice daily. Well tolerated; no significant efficacy difference vs placebo.

Not a GH or body-composition endpoint.

Community protocol — not clinically establishedCommunity guide
RouteSubcutaneous
Frequency1-3x daily
Starting100 mcg once daily at bedtime, fasted, about week 1
Escalation200 mcg weeks 2-3 (1x or split 2x)
Target200-300 mcg/day, 1-2x daily, weeks 4-8. Per-shot ceiling 100-300 mcg.
Cycle8-12 weeks on, then 4 weeks off

"No published human trial has validated GH-optimization or body-composition endpoints."

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

Not FDA-approved; endocrine risks; avoid self-administration

No well-established interaction profile for non-approved peptides; avoid combining multiple research compounds; discuss meds with clinician.

CV 1 of 5 — No solid direct cardiovascular outcomes evidence; any benefit is indirect or unproven.